Topics

Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

16:34 EST 14 Feb 2020 | BioPortfolio Reports

Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2019


Summary


Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. pipeline Target constitutes close to 6 molecules. The latest report Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2019, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. Prolyl 4 hydroxylases P4H are iron and 2oxoglutamatedependent dioxygenase enzymes and hypoxiainducible transcription factor HIFP4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. The molecules developed by companies in PreRegistration, Phase III and Phase I stages are 2, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease Renal Anemia, Anemia and Chemotherapy Induced Anemia.


Furthermore, this report also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.

The report reviews Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics and enlists all their major and minor projects

The report assesses Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11. development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Transmembrane Prolyl 4 Hydroxylase Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Enzymes
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...